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Abstract
In multiple myeloma (MM), malignant plasma cells reside in the bone marrow, where they accumulate in close contact with
stromal cells. The mechanisms responsible for the chemotaxis of malignant plasma cells are still poorly understood. Thus,
we investigated the mechanisms involved in the chemotaxis of MDN and XG2 MM cell lines. Both cell lines strongly
expressed CCR9, CXCR3 and CXCR4 chemokine receptors but only migrated toward CXCL12. Activation of CXCR4 by CXCL12
resulted in the association of CXCR4 with CD45 and activation of PLCb3, AKT, RhoA, IkBa and ERK1/2. Using siRNA-silencing
techniques, we showed CD45/CXCR4 association is essential for CXCL12-induced migration of MM cells. Thymoquinone
(TQ), the major active component of the medicinal herb Nigella sativa Linn, has been described as a chemopreventive and
chemotherapeutic compound. TQ treatment strongly inhibited CXCL12-mediated chemotaxis in MM cell lines as well as
primary cells isolated from MM patients, but not normal PBMCs. Moreover, TQ significantly down-regulated CXCR4
expression and CXCL12-mediated CXCR4/CD45 association in MM cells. Finally, TQ also induced the relocalization of
cytoplasmic Fas/CD95 to the membrane of MM cells and increased CD95-mediated apoptosis by 80%. In conclusion, we
demonstrate the potent anti-myeloma activity of TQ, providing a rationale for further clinical evaluation.
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Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder
that accounts for approximately 10% of all hematologic cancers
[1] and is the second most prevalent hematologic malignancy.
Although some therapeutic drugs and novel therapies are
available, MM remains incurable, and the median survival time
for MM patients is 3 to 5 years [2,3]. Several chemotherapeutic
agents (e.g., vincristine, dexamethasone and melphalan) are
currently used to treat MM. However, these drugs increase the
risk of developing secondary hematologic malignancies such as
therapy-related myelodysplatic syndromes [4]. Therefore, there is
a need to further identify the factors and mechanisms that are
responsible for maintaining the survival of MM cells and
mediating tumorigenesis and drug resistance. Although the
presence of circulating malignant plasma cells has been demon-
strated in more than 70% of patients diagnosed with MM [5], the
survival of MM cells requires their migration from the blood to the
bone marrow (BM) niches (known as homing) and active
navigation from one area to another within the BM [6]. Several
studies have revealed the important role of chemokines and their
receptors in the chemotaxis and pathogenesis of MM cells [7,8].
MM cells express variable levels of the chemokine receptors
CXCR3, CXCR4, CCR1, CCR5, and CCR6 and show variable
responses to their cognate ligands CCL3, CXCL12 and CCL5
[9,10]. In addition, Vande Broek et al. reported the involvement of
CCR2 and its ligands CCL2, CCL8 and CCL7 in the migration of
human MM cells towards the BM [11].
Of the numerous chemokine receptors that are expressed,
CXCR4 is the most highly expressed chemokine receptor in many
cancer cells [12]. CXCR4 ligand, CXCL12, is strongly expressed
in lung, liver, bone marrow and lymph nodes, which are all
common metastatic destinations for many types of cancer.
Moreover, upregulation of CXCR4 has frequently been observed
in various cancers, including colon carcinoma, lymphoma, breast
cancer, glioblastoma, leukemia, prostate cancer, oral squamous
cell carcinoma and pancreatic cancer [9,13,14,15,16,17,18].
Similarly, several studies have shown that CXCR4 is also the
most abundant and functional of the chemokine receptors
expressed by MM cells, and thus may play a major role in the
pathogenesis of the disease. Indeed, published data suggest the
involvement of CXCL12/CXCR4 in the maintenance and
survival of MM cells in both in vivo and in vitro models [19,20].
Nevertheless, the signaling pathways activated downstream of
CXCR4 after stimulation with CXCL12 in MM cells remain
poorly defined.
Recently, natural antioxidants have been used as adjuvants in
combination with chemotherapy to reduce the side effects and
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antioxidants are very effective at inducing the growth arrest of
human colon cancer cells [22]. In recent years, numerous natural
products have been evaluated for their use in cancer treatment
[23,24].
Thymoquinone (TQ), the most abundant component of black
seed oil extract, is the active compound that is primarily
responsible for many of the seed’s antioxidant and anti-
inflammatory effects [25]. TQ exerts an anti-neoplastic effect
and may be a promising dietary chemopreventive agent. In
particular, several studies have illustrated the pro-apoptotic and
growth arrest effects of TQ on several cancer cell lines [26]. In
addition, TQ exerts inhibitory effects on the cell proliferation in
many types of cancer cells, including breast and ovarian
adenocarcinoma [27], colorectal cancer [28], human pancreatic
adenocarcinoma and uterine sarcoma [25], neoplastic keratino-
cytes [29], human osteosarcoma [30] and fibrosarcoma and lung
carcinoma [31]. An in vivo study by Badary and El-Din showed
that TQ-treatment inhibited a fibrosarcoma tumor incidence and
burden by 43 and 34%, respectively [32]. Recently, Ravindran et
al. published a detailed study of the anti-proliferative, anti-
inflammatory and chemosensitization activities of TQ in myeloid
leukemia cells [33]. In this study, they also compared the effect of
TQ on various cancer cells, and showed that TQ exerts an anti-
proliferative effect on MM (U266) cells, although the authors did
not address the underlying mechanisms.
In the present study, we investigated the chemokines responsible
for and the precise mechanisms involved in MM cell chemotaxis.
Although TQ is known to modulate the proliferation of and
induce growth arrest in numerous cancer cells, very few data are
available concerning its effect on MM cells. For this reason, we
also evaluated the efficiency of TQ in modulating the chemotaxis
and survival of MM cells.
Materials and Methods
Cells and reagents
IL-6–dependent human myeloma MDN and XG-2 cell lines
[34,35] were obtained from the Veterinary Serum and Vaccine
Research Institute (VSVRI, Cairo, Egypt). Both cell lines were
maintained in RPMI 1640 containing 10 mM HEPES, 10% fetal
calf serum (FCS; Biowittaker, Walkersville, MD) and 1% L-
glutamate (R-10 medium) supplemented with 3 ng/mL IL-6
(Peprotech, Rocky Hill, NJ). The cell cultures were free of
Mycoplasma, as assessed by an enzyme-linked immunosorbent assay
(ELISA) kit (Boehringer, Mannheim, Germany).
BM aspirate samples obtained from 9 patients with MM were
kindly provided by Dr. Douaa Sayed (South Egypt Cancer
Institute, Assiut University). Plasma cells were isolated from the
BM aspirates by positive selection using anti-CD138 antibody-
coated immunomagnetic beads according to the manufacturer’s
instructions (MACS, Miltenyi Biotech). MACS purification
consistently resulted in a .95% pure primary MM cell population
(as determined by monitoring cell-surface expression of CD38 and
CD45) and a viability of .90% (as determined using the trypan
blue exclusion method). Peripheral blood mononuclear cells
(PBMCs) from healthy donors were purified using a standard
Ficoll-Paque gradient centrifugation method according to the
instructions of the manufacturer (Amersham Pharmacia, Uppsala,
Sweden). Briefly, the heparinized blood was diluted 1:1 in
phosphate-buffered saline (PBS), carefully layered over the
Ficoll-Paque gradient, and centrifuged for 20 min at 1,0206 g.
The cell interface layer was carefully harvested, and the cells were
washed twice in PBS and resuspended in RPMI 1640. In some
experiments, cells were pre-treated using one or a combination of
the following compounds (unless otherwise stated, all compounds
were obtained from Calbiochem, San Diego, CA): (i) 10 mg/ml
brefeldin A (Sigma-Aldrich) or 1 mM cycloheximide (Sigma-
Aldrich) at 37uC for 30 min; (ii) TQ (Sigma-Aldrich, UK) at
37uC for various time lengths (as indicated in the figure legends);
and (iii) 5 mg/ml AMD3100 (AMD, a CXCR4 antagonist),
100 nM or 1 mM wortmannin (WM, a phosphatidylinositol-3
kinase [PI3K] inhibitor that inhibits all classes of PI3K at 1 mM
but is selective for class I PI3K at 100 nM), 10 mM PD98059 (a
mitogen activated protein kinase [MEK1/2] inhibitor), 10 mM
SB203580 (a P38 MAPK inhibitor), 100 nM U73122 (a
phospholipase C [PLC] inhibitor) or its inactive control U73343,
1 mM SN50 (an inhibitor of NF-kB nuclear translocation), 50 mg/
ml Y27632 (a RhoA inhibitor), 100 ng/ml pertussis toxin (PTX,
an inhibitor of heterotrimeric G-protein signaling), 5 mM SH5 (a
PDK1 inhibitor, Alexis, Coger France), Na3VO4 (a protein
tyrosine phosphatase inhibitor, Sigma-Aldrich) or DMSO at
37uC for one hour.
Ethics statement
BM aspirate samples were obtained from patients at Assiut
University Hospital. All aspects of this study were approved by
Assiut University’s ethical committee, and all patients provided a
written informed consent accordingly to the Declaration of
Helsinki.
Small interfering RNA (siRNA)-mediated knockdown
SiRNA-mediated knockdown of CD45 was performed using
synthetic duplex RNA oligonucleotides as previously described
[36]. The 19-nucleotide target for the CD45 and control siRNAs
was GUCUUUGUCACAGGGCAAA (Dharmacon, Inc., Boul-
der, CO). MM cells were transfected with 100 nM siRNA by
electroporation using an Amaxa system (Amaxa GmbH, Cologne,
Germany), and CD45 siRNA-mediated knockdown was con-
firmed after 48 h by flow cytometry.
Flow cytometry
Cell surface antigen expression was determined by single-
parameter fluorescence-activated cell sorter (FACS) analysis using
the following monoclonal antibodies (mAbs): (i) PE-conjugated
anti-CCR1, anti-CCR3, anti-CCR5 (clone 45531.111), anti-
CCR7 (clone 150503), anti-CCR6 (clone 53103.111), anti-
CXCR3, anti-CXCR4 (clone 44717.111) and anti-CXCR5, all
purchased from R&D Systems; and (ii) PE-conjugated anti-CD38,
anti-CD138, anti-CD45 and anti-CD95 (IgG1) mAbs, FITC-
conjugated anti-CD62L, anti-VLA4, anti-a4b1, anti-a4b7 and
anti-CD54 mAbs, and FITC- and PE-conjugated mouse isotype-
matched control mAbs, all purchased from BD Biosciences. To
detect the expression of cytoplasmic CD95, MM cells were
permeabilized using a Cytofix/Cytoperm kit (BD Biosciences)
according to the manufacturer’s instructions before being stained
with PE-conjugated anti-CD95 mAb or mouse IgG1. A FACS-
can
TM flow cytometer with CellQuestH software (BD Biosciences)
was used for data acquisition and analysis. After gating on viable
cells, 15,000 events per sample were analyzed. For each marker,
the threshold of positivity was defined beyond the nonspecific
binding observed in the presence of a relevant isotype control
mAb.
In vitro chemotaxis assays
The chemokine-dependent migration of MM cells and PBMCs
was measured using an in vitro 2-chamber migration assay (using
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followed by flow cytometry analysis. All chemotaxis assays were
performed in pre-warmed migration buffer (RPMI 1640 contain-
ing 1% FCS). A total of 600 ml of migration buffer alone or
supplemented with either CCL3, CCL4, CCL5, CCL25, CXCL9,
CXCL10 (all at 500 ng/ml) or CXCL12 (at 250 ng/ml) (all from
R&D Systems) was added to the lower chamber and 10
5 cells in
migration buffer were added to the upper chamber. The plates
were then incubated for 3 h at 37uC, and input cells and
transmigrated cells were centrifuged, fixed in 300 mlo f1 6
PBS+1% formaldehyde and counted for 60 seconds using a
FACscan
TM flow cytometer (Beckton Dickinson). The percentage
of migration was calculated as the percentage of input cells that
migrated to the lower chamber. To calculate the percentage of
specific migration induced by chemokines, the percentage of cells
migrating to medium alone was subtracted from the percentage of
cells migrating to medium with chemokines.
To test the effect of various inhibitors on chemotaxis, cells were
pre-treated as detailed in the ‘‘cells and reagent’’ section before
their addition to the upper chamber. The percentage of inhibition
of specific migration in the presence of inhibitors was calculated as
follows: [1 - (specific migration of treated cells/specific migration
of untreated cells)]6100.
Western blots
Untreated and TQ-treated myeloma cells (5610
6 cells/ml in
pre-warmed R-10 medium without FCS) were stimulated for
2 min at 37uC with or without 250 ng/ml CXCL12. Lysates were
prepared as previously described [37]. Equal amounts of total
cellular protein were resolved using SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and analyzed by western blotting.
Antibodies recognizing phospho-PKB/AKT (S473), PKB/AKT,
phospho-ERK1/2 (T202/Y204), phospho-IkBa (S32/36), IkBa,
phospho-PLCb3 (S537), PLCb3, phospho-P38 MAPK (T180/
Y182), P38 MAPK, and pan CD45 (all from New England
Biolabs, Beverly, MA) or ERK1/2 (Santa Cruz Biotechnology,
Santa Cruz, CA) were used in combination with horseradish
peroxidase-conjugated secondary antibodies. Protein bands were
detected using enhanced chemiluminescence reagents (ECL,
Supersignal Westpico chemilumiscent substrate, Perbio, Bezons,
France), and the ECL signal was recorded on hyperfilm ECL. To
quantify band intensities, films were scanned, saved as TIFF files
and analyzed using NIH Image J software.
For immunoprecipitation, cell lysates containing equal amounts
of protein were clarified by incubation with Protein A-Sepharose
CL-4B or GammaBindTM-Sepharose beads (Amersham Biosci-
ences) for 1 h at 4uC. The Sepharose beads were removed by brief
centrifugation, and the supernatants were incubated with specific
primary antibodies for 2 h at 4uC. Subsequently, immunoprecip-
itation of the antigen/antibody complexes was performed by
overnight incubation at 4uC with 50 ml of Protein A-Sepharose or
GammaBindTM-Sepharose (50% suspension). Nonspecific pro-
teins were removed by washing the beads three times with PBS.
Immunoprecipitated complexes were solubilized in 50 mlo f2 6
Laemmli buffer and further analyzed by western blotting as
described above. In some experiments, MDN and XG2 cells were
incubated with or without 2 mM methyl-beta-cyclodextrin
(MbCD) for 30 min or 10 mM TQ for 1 h prior to the 2 min
incubation with or without 250 ng/ml CXCL12 and subsequent
cell lysis.
To assess RhoA activation, cells (5610
6 per condition) were
starved for 2 h in pre-warmed R-10 medium without FCS,
incubated for 2 min at 37uC with or without 250 ng/ml CXCL12,
and lysed as described above (using 200 ml of lysis buffer). After
centrifugation, a 15 ml aliquot of the supernatant was kept as total
lysate sample. The remaining supernatant (185 ml) was incubated
for 16 h at 4uC with GST-C21 [38] precoupled to glutathione–
agarose beads (Sigma, France). Beads were washed using an excess
of lysis buffer and the active RhoA (RhoAGTP pulled down from
the lysate and bound to the fusion protein/beads) was eluted using
Laemli sample buffer. Analysis by SDS-PAGE and western
blotting using an anti-RhoA mAb (Santa Cruz Biotechnology,
Santa Cruz, CA) was subsequently performed on both the total cell
lysates and the samples eluted in Laemli buffer to detect total
RhoA and RhoAGTP, respectively.
Apoptosis Assays
To assess CD95-mediated apoptosis, untreated and TQ-treated
myeloma cells (10
6 cells/ml) were incubated for 30 min with or
without a general caspase inhibitor (Caspase inhibitor II;
Calbiochem, San Diego, CA), prior to incubation for 24 h at
37uC with 1 mg/ml B-G27 (IgG2a, Diaclone SA, Besanc ¸on,
France) or mouse IgG2a as a control. Myeloma cells were then
collected, and the percentage of cells undergoing apoptosis was
determined as described below.
Cells were washed and incubated in PBS containing 30%
human AB serum at 4uC for 30 min prior to staining with
Annexin V-FITC and PI for 15 min at 25uC using a commercial
kit according to the manufacturer’s instructions (ABCam,
Canada). Cells were analyzed by flow cytometry within 1 hour
of staining, and apoptotic cells were determined as PI
neg/Annexin
V
pos, dead cells as double positive and viable cells as double
negative.
Statistical analysis
Data were analyzed using SPSS software version 16 and are
expressed as means 6 SEM. Differences between groups were
assessed using the analysis of variance (ANOVA) method. Data
were considered significant if the calculated P values were ,0.05.
Results
CXCL12-mediated MM cell chemotaxis involves PLC,
PI3K, RhoA, NF-kB and ERK1/2
We first investigated the surface expression of various
chemokine receptors on MDN and XG2 MM cell lines using
flow cytometry. Our results showed that XG2 cells strongly
expressed CCR9, CXCR3 and CXCR4, expressed low levels of
CCR1, CCR5, CCR7 and CXCR5, and did not express CCR6
(Figure S1). A similar expression pattern was observed in MDN
cells (data not shown). To further analyze the functionality of the
chemokine receptors expressed by MM cells, we performed a
chemotaxis assay to analyze the ability of MM cells to migrate
toward 500 ng/ml CCL3, CCL4, CCL5 (CCR1, CCR3 and
CCR5 ligands, respectively); CCL25 (CCR9 ligand); CXCL9 or
CXCL10 (CXCR3 ligand); or 250 ng/ml CXCL12 (CXCR4
ligand). Both MM cell lines only exhibited a specific migratory
response to CXCL12; the percentages of cells specifically
migrating to CXCL12 were 3062.9% and 3764.7% for MDN
and XG2 cells, respectively (Figure 1A). The CXCL12-mediated
MM cell chemotaxis was dependent on the interaction of
CXCL12 with CXCR4. Indeed, the specific migration towards
CXCL12 was totally inhibited in MM cells pretreated with AMD
(Figure 1A), a specific CXCR4 antagonist that inhibits the
binding and function of CXCL12 with high affinity and potency
[39].
The signaling pathways involved in MM cell chemotaxis are
poorly defined; therefore, we analyzed the effect of various
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Migration of MDN cells toward CXCL12 was strongly inhibited
by AMD, PTX and U73122 (9463.5%, 8463.2% and 8262.9%
inhibition of migration, respectively; n=6) and to a lesser extent
by 1 mM of WM, SH5, Y27632, SN50, PD98059 and Na3VO4
(4561.5%, 4261.9%, 2561.8%, 3562.1%, 2061.8% and
3062% inhibition of migration, respectively; n=6) (Figure 1B).
Similarly, the migration of XG2 cells toward CXCL12 was also
strongly inhibited by AMD, PTX and U73122 and to a lesser
extent by 1 mM WM, SH5, Y27632, SN50, PD98059 and
Na3VO4 (Figure 1C). In all experiments, the addition of DMSO,
100 nM WM, U73343 or SB203580 had no effect on the
CXCL12-mediated chemotaxis of MM cells. The near total
inhibition of migration toward CXCL12 observed in the presence
of the CXCR4 antagonist (AMD) and the inhibitor of heterotri-
meric G-proteins (PTX) illustrated the specificity of MM cell
migration and confirmed that it was dependent on the interaction
of CXCL12 with its receptor CXCR4 on the surface of MM cells.
Importantly, the use of selective inhibitors revealed that MM cell
migration toward CXCL12 was strongly dependent on PLC
activity and to a lesser extent on PI3K, RhoA, NF-kB and ERK1/
2 signaling. In addition, our results suggested that only class II
PI3Ks were involved in MM cell migration toward CXCL12,
since only the addition of 1 mM WM (which inhibits all classes of
PI3K) but not 100 nM WM (which selectively inhibits Class I
PI3K) impaired CXCL12-induced MM cell migration.
CXCL12 strongly enhances PLCb3, AKT, IkBa and ERK1/2
phosphorylation and the activation of RhoA via PI3K in
MM cells
To better characterize the molecular mechanisms by which
CXCL12 induces the chemotaxis of MM cells, we investigated the
effect of CXCL12 on the activation of various downstream
effectors of CXCR4. Since CXCL12-mediated chemotaxis of MM
cells involves PLC, PI3K, RhoA, NF-kB and ERK1/2, we
specifically investigated the phosphorylation status of PLCb3,
AKT, IkBa and ERK1/2 and the activation status of RhoA (an
important protein for the adhesion of MM cells) following the
stimulation of MDN cells with CXCL12 (Figure 2). In addition,
P38 phosphorylation was assessed and used as a negative control,
since we showed that its specific inhibitor, SB203580, did not
modulate CXCL12-induced MM cell migration.
Although PLCb3 showed some levels of phosphorylation under
basal conditions, CXCL12 increased its phosphorylation level by a
factor of 1.9 fold (from 8066 to 14969.7; n=6). CXCL12-
induced increase in PLCb3 phosphorylation was abolished by pre-
treatment with AMD (6067.1; n=6), U73122 (8368.2; n=6) or
PTX (8867.9; n=6). In contrast, the addition of U73343, the
inactive form of the PLC inhibitor U73122, did not inhibit
CXCL12-induced increase in PLCb3 phosphorylation (data not
shown). To measure PI3K activity, we investigated the level of
PKB/AKT phosphorylation (p-AKT) in CXCL12-stimulated
MM cells. We found that CXCL12 strongly induced AKT
phosphorylation (from 1564.7 to 18566.4; n=6) and that this
effect was abolished by pre-treatment with AMD, WM or SH5
(2064.1, 2265.1 and 1363, respectively; n=6).
Similarly to PLCb3, we also detected a basal level of IkBa
phosphorylation, which was increased by a factor of 1.7 following
CXCL12 stimulation (from 12866 to 22268.8; n=6). The
Figure 1. Chemotactic response of MM cells. Migratory responses
of MDN and XG2 cells to the indicated chemokines were determined
using Transwell plates. After incubation for 3 h at 37uC, the chemotactic
response to CCL3, CCL4, CCL5, CCL25, CXCL9, CXCL10 (all at 500 ng/ml)
or CXCL12 (at 250 ng/ml) was determined by flow cytometry. Some
cells were pre-incubated for one hour at 37uC with AMD, before being
used for the chemotaxis assay in migration medium with 250 ng/ml
CXCL12. The experiment was performed in triplicate, and results are
expressed as the mean percentage of specific migration 6 SEM in
response to each chemokine (A). MDN (B) and XG2 (C) cells were
incubated for one hour at 37uC with medium, DMSO or various
inhibitors, before being used for a chemotaxis assay in migration
medium with or without 250 ng/ml CXCL12. Data from six independent
experiments is expressed as the mean percentage of inhibition of
specific migration 6 SEM. PTX=pertussis toxin; SB=SB203580.
*P ,0.05and ** P,0.001.
doi:10.1371/journal.pone.0023741.g001
TQ Impairs CXCL12-Mediated MM Cell Chemotaxis
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e23741CXCL12-induced IkBa phosphorylation was strongly inhibited by
the addition of AMD and WM (3163.6 and 12067.7,
respectively, n=6) but only partially decreased by SH5
(18568.3; n=6). CXCL12 also strongly induced ERK1/2
phosphorylation (from 763.4 to 20368.7; n=6), and this effect
was totally inhibited by pre-treatment with AMD, PD98059 or
WM (662.2, 1663.2 and 2465, respectively; n=6). As expected,
CXCL12 did not modulate P38 phosphorylation. Our results also
showed that only low levels of RhoAGTP were detected in
unstimulated MDN cells (4264; n=6) and that RhoA activation
was strongly enhanced by CXCL12 stimulation (23767.9; n=6).
The addition of AMD, WM or Y27632 abolished the CXCL12-
mediated increase of RhoAGTP (4266, 3463 and 2564,
respectively; n=6). Similar results were obtained when using
XG2 cells instead of MDN cells in these assays, and we also
determined that CXCL12-induced phosphorylation of ERK1/2,
IkBa and AKT peaked between 1 and 5 min in both MM cell
lines (data not shown).
CXCL12-induced MM cell chemotaxis requires the
association of CXCR4 with CD45
Fernandis et al. previously demonstrated that the membrane
tyrosine phosphatase CD45 interacts with CXCR4 and regulates
the CXCR4-mediated chemotactic activity of cells from the Jurkat
human T-cell line [40]. Using co-immunoprecipitation and
immunoblotting techniques, we showed that CXCL12 stimulation
similarly induced a physical association between CXCR4 and
CD45 in both MM cell lines tested (Figure 3A and 3B). This
association was rapid, reaching its maximum level at 2 min post-
stimulation. Using siRNA silencing techniques, we successfully and
specifically abrogated CD45 expression in these MM cell lines
(Figure 3C) and showed that CD45 siRNA-transfected (but not
control siRNA-transfected) MDN and XG2 cells lost their ability
to migrate in response to CXCL12 (Figure 3D). Our results thus
illustrate the critical role of CD45 expression and interaction with
CXCR4 in the CXCL12-induced chemotaxis of MM cells.
Thymoquinone inhibits the chemotaxis of MM cells in a
dose- and time-dependent manner
MDN and XG2 MM cells were cultured in the presence or
absence of TQ at various concentrations, and we subsequently
determined their ability to migrate in response to CXCL12. The
percentages of specific migration of untreated MDN and XG2
cells to CXCL12 were 3163.2% and 3962.9%, respectively. Our
results showed that pre-treatment with TQ strongly impaired the
chemotaxis of both MDN and XG2 cells toward CXCL12. This
effect was dose-dependent and peaked at 10 mM TQ; at this dose,
the percentages of specific migration of TQ-treated MDN and
XG2 cells toward CXCL12 were only 2% and 4%, respectively
(Figure 4A). This inhibition of MM cell migration did not result
from a TQ-mediated cytotoxic effect, since the addition of TQ
(even at the highest concentration) had no effect on cell viability as
assessed by the trypan blue exclusion method (data not shown).
MDN and XG2 cells were then cultured in the presence of 10 mM
TQ for increasing lengths of time prior to assessing their migration
toward CXCL12. We found that the maximal TQ-induced
inhibition of CXCL12-mediated MM cell chemotaxis was
observed following a one to six hour pre-treatment with TQ.
Indeed, the chemotactic response of MDN cells was decreased by
87.9% (n=6) and the response of XG2 cells was decreased by
95% (n=6) after pre-incubation with TQ for 1 h (Fig. 4B).
We then evaluated the effects of TQ on the CXCL12-induced
migration of primary MM cells (purified from bone marrow
aspirates of MM patients) and PBMCs isolated from healthy
donors. In the absence of TQ, 3964.3% (n=9) of primary MM
cells and 3063.7% (n=9) of PBMCs from healthy donors
specifically migrated in response to CXCL12. Following TQ
pre-treatment, MM cell migration toward CXCL12 was inhibited
by 74% (from 3964.3% to 1063%; n=9), whereas the migratory
capacity of PBMCs from healthy donors toward CXCL12 was not
affected (from 3063.7% to 3465.2%; n=9) (Fig. 4C). Using
similar culture conditions, the percentage of viable cells (Annexin-
V
neg/PI
neg) was similar in both untreated and TQ-treated primary
MM cells (80.863.3 and 79.562.6, respectively; n=9) and
Figure 2. CXCL12 induces the phosphorylation of PLCb3, AKT,
ERK1/2, and IkBa and the activation of RhoA in MDN cells. MDN
cells were incubated for one hour at 37uC in medium either with or
without various inhibitors (WM used at 1 mM). Cells were then
incubated for 2 min with medium or 250 ng/ml CXCL12 prior to being
lysed. Proteins in the cell lysates were resolved on a 7% acrylamide gel.
The phosphorylation levels of PLCb3 (p-PLCb3), ERK1/2 (p-ERK1/2), AKT
(p-AKT), IkBa (p- IkBa) and P38 (p-P38) and the activation level of RhoA
(RhoAGTP) were corrected for total relevant protein (T-PLCb3, T-ERK1/2,
T-AKT, T- IkBa, T-P38 and T-RhoA) on stripped blots. A representative
blot for each downstream effector from 6 independent experiments is
shown (left panel); all results are expressed as mean values of
normalized specific phosphorylation 6 SEM from six separate
experiments (right panel). PTX=pertussis toxin; PD=PD98059;
SB=SB203580. *P,0.05.
doi:10.1371/journal.pone.0023741.g002
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Therefore, our results showed that TQ specifically inhibited the
CXCL12-induced chemotaxis of MM cells without inducing any
cytotoxic effect. Importantly, this effect was observed when using
cells from two different MM cell lines, but also when using primary
plasma cells isolated from the BM of MM patients.
Thymoquinone decreases the surface expression of
CXCR4 on MM cells and CXCL12-induced CXCR4/CD45
interactions
We subsequently investigated the mechanisms involved in TQ-
mediated inhibition of MM cell chemotaxis. For this purpose, we
first assessed the CXCR4 expression levels in both MDN and
XG2 cells before and after incubation with 10 mM TQ. In the
absence of TQ, CXCR4 was strongly expressed by both MM cell
types (mean fluorescence intensity, MFI=52165.2 and 44867.1
in MDN and XG2 cells, respectively; n=5). However, TQ
strongly decreased CXCR4 surface expression of both MDN
(MFI=4864.9; n=5) and XG2 (MFI=1667.2; n=5) cells
(Figure 5A). We next investigated whether the CXCL12-
mediated interaction of CD45 with CXCR4, which we showed
was important for CXCL12-induced chemotaxis of MM cells, was
also affected by TQ. To address this question, MDN and XG2
cells were cultured in medium with or without 10 mMT Qo r
2m MM bCD (which extracts cholesterol from the cell membrane
and disrupts lipid rafts) prior to stimulation with CXCL12. We
showed that the CXCL12-induced interaction of CXCR4 with
CD45 was strongly impaired by pre-treatment with TQ
(Figure 5B). However, this effect may result from the reduced
expression of CXCR4 on the surface of MM cells rather than from
a direct TQ effect on CXCR4/CD45 interaction. Finally, we
showed that pre-treatment with MbCD completely abolished the
CXCL12-induced association of CXCR4 with CD45 in both
MDN and XG2 cells, suggesting that lipid rafts are also required
for CXCL12-induced MM cell chemotaxis. Similarly to previous
reports showing that MbCD treatment did not modulate the
expression of surface receptors, such as B Cell Receptor, CD4 or
CXCR4 [41,42], we showed that MbCD treatment did not
modulate the expression levels of CXCR4 or CD45 on the surface
of MM cells (data not shown).
TQ increases CD95 expression levels and susceptibility to
Fas-mediated apoptosis of MM cells
We assessed the effect of TQ pre-treatment on the surface
expression of various markers that could be involved in the
chemotaxis and viability of MM cells. TQ did not significantly
modulate surface expression levels of LFA-1 (CD11a/CD18),
ICAM1 (CD54), CD62L, CD5, CD10, CD80, CD86, CD23,
CD38, CD44 or CD27 (data not shown). In contrast, the surface
expression level of CD95 was strongly increased in TQ-treated
MDN cells (MFI=2468.9 and 233611 in untreated and TQ-
treated cells, respectively; n=8) and XG2 cells (MFI=1567 and
289612 in untreated and TQ-treated cells, respectively; n=8)
(Figure 6A). The increased CD95 surface expression observed in
TQ-treated cells was inversely correlated with a decrease in
Figure 3. CXCL12-induced interaction of CD45 with CXCR4 is
required for MM cell chemotaxis. (A) MDN and XG2 cells were
either unstimulated (0) or stimulated with 250 ng/ml CXCL12 (+), and
lysed at the indicated time points following CXCL12 stimulation (in
min). Total cells lysates (equivalent to 50 mgo fp r o t e i n )w e r e
immunoprecipitated (IP) using a CXCR4 antibody. The immune
complexes were resolved on a 7% acrylamide gel, transferred to a
nitrocellulose membrane, and immunoblotted with an anti-CD45
antibody. Equal protein loading levels were confirmed by resolving
50 mg of total cell lysates by SDS-PAGE and immunoblotting with an
anti-actin antibody. A representative blot from 6 independent
experiments is shown. (B) Results from figure 3A are expressed as
mean normalized CD45 levels 6 SEM from six separate experiments. (C)
Untransfected (gray filled histograms; 3), control siRNA-transfected (thin
dotted line histograms; 4) and CD45 siRNA-transfected (bold solid line
histograms; 2) MDN (left panel) and XG2 (right panel) cells were
cultured for 48 hours, stained with an anti-CD45 antibody and analyzed
by flow cytometry. Cells stained with an isotype-matched mAb are
shown as the negative control (thin solid line histograms; 1). (D) Specific
migration of untransfected, control siRNA- and CD45 siRNA-transfected
cells was assessed in migration medium with or without 250 ng/ml
CXCL12 by flow cytometry. Data is expressed as the mean percentage
of specific migration 6 SEM from six independent experiments for both
MDN (hatched bars) and XG2 (closed black bars) cells. ** P,0.004.
doi:10.1371/journal.pone.0023741.g003
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mediated CD95 up-regulation was abolished by the addition of
10 mg/ml brefeldin A but not 1 mM cycloheximide (Figure 6C),
Figure 4. Dose- and time-dependent effects of TQ on CXCL12-
mediated MM cell chemotaxis. (A) MDN (hatched bars) and XG2
(closed black bars) cells were incubated for 2 hours in medium with or
without increasing concentrations of TQ, and their chemotactic
response to 250 ng/ml CXCL12 was analyzed by flow cytometry. The
experiment was performed in triplicate, and results are expressed as the
mean percentage of specific migration 6 SEM. * P,0.05, ** P,0.02. (B)
MDN and XG2 cells were incubated for the indicated time periods with
10 mM TQ prior to assessing their chemotactic response to 250 ng/ml
CXCL12. The experiment was performed in triplicate, and results are
expressed as the mean percentage of specific migration 6 SEM. *
P,0.05, ** P,0.02. (C) Primary MM cells isolated from the BM of
patients and PBMCs from healthy donors were incubated in R-10
medium for six hours prior to incubation in medium with (gray bars) or
without (open bars) 10 mM TQ for one hour at 37uC. Their chemotactic
response to 250 ng/ml CXCL12 was subsequently assessed by flow
cytometry. The experiment was performed in triplicate with cells from
nine different donors, and the results are expressed as the mean
percentage of specific migration 6 SEM. ** P,0.02. (D) Primary MM
cells isolated from the BM of patients and PBMCs from healthy donors
were cultured for 6 hours in migration medium before being incubated
for one hour at 37uC in medium either with (hatched bars) or without
(open bars) TQ. The percentage of viable cells was determined by
Annexin-V staining and flow cytomety. Results are expressed as the
mean percentage of viable cells 6 SEM from nine separate experiments.
doi:10.1371/journal.pone.0023741.g004
Figure 5. TQ decreases CXCR4 expression on MM cells and
CXCL12-induced CXCR4/CD45 association. (A) MDN (left) and
XG2 (right) cells were incubated for one hour at 37uC in medium with
(bold solid line histograms) or without (gray filled histograms) 10 mM
TQ, before being stained with an anti-CXCR4 mAb and analyzed by flow
cytometry. Cells stained with an isotype-matched mAb are shown as a
negative control (thin dotted line histograms). (B) MDN (left) and XG2
(right) cells were incubated with or without 2 mM MbCD for 30 min at
37uCo r1 0mM TQ for one hour prior to incubation for 2 min in medium
with (+) or without (0) 250 ng/ml CXCL12. The cells were then lysed and
immunoprecipitated (IP) with a CXCR4 antibody. The immune
complexes were separated on a 7% SDS-PAGE gel, transferred to a
nitrocellulose membrane, and immunoblotted with an anti-CD45
antibody (upper blot). Equal protein loading was confirmed by running
50 mg of the total lysates on a SDS-PAGE gel and immunoblotting using
an anti-actin antibody (lower blot). A representative blot from 6
independent experiments is shown. (C) Results from figure 5C are
expressed as mean normalized CD45 levels 6 SEM from six separate
experiments.
doi:10.1371/journal.pone.0023741.g005
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intracellular CD95 to the cell surface without inducing any de novo
CD95 protein synthesis.
Since TQ treatment increased CD95 expression on MM cells,
we investigated whether TQ could also increase their susceptibility
to CD95-mediated apoptosis. For this purpose, both untreated and
TQ-treated MDN and XG2 cells were incubated for 24 h in the
presence of 1 mg/ml B-G27 mAb (agonistic CD95 mAb) prior to
staining with Annexin-V and PI to discriminate among viable,
necrotic/dead and apoptotic cells (Figure 6D&E). The percent-
age of apoptotic MDN cells increased from 9.362.7% to
88.764.6% (n=9) when the cells were treated with TQ
(Figure 6F). Similarly, the percentage of apoptotic XG2 cells
increased from 11.463.7% to 84.165.2% (n=9) when cells were
treated with TQ (Figure 6F). In addition, we showed that the
effect of TQ on Fas-mediated apoptosis was completely inhibited
Figure 6. TQ increases the surface expression of CD95 and susceptibility of MM cells to Fas-mediated apoptosis. MDN and XG2 cells
were incubated for one hour at 37uC in medium either with (bold solid line histograms) or without (gray filled histograms) 10 mM TQ prior to
assessing the levels of extracellular (A) and intracellular (B) CD95 expression by flow cytometry. Cells were stained with an isotype-matched mAb are
shown as a negative control (thin line histograms). One representative data set from eight independent experiments is shown. (C) MDN (left) and XG2
(right) cells were incubated for 30 min at 37uC with medium alone (0), 10 mg/ml brefeldin A (BFA) or 1 mM cycloheximide (CHM) prior to incubation
for one hour with (gray bars) or without (open bars) 10 mM TQ. CD95 surface expression levels were assessed by flow cytometry and results are
expressed as the mean fluorescence intensity (MFI) value 6 SEM from nine separate experiments. (D & E) MDN and XG2 cells were incubated for one
hour at 37uC in medium either with (E) or without (D) 10 mM TQ prior to starvation for 24 h in the presence of 1 mg/ml agonistic CD95 mAb (clone BG-
27). The percentage of cells undergoing apoptosis was determined by flow cytometry based on the PI/Annexin V staining patterns. The percentage of
apoptotic cells was consistently below 10% in all cells incubated for 24 h in the presence of a CD95-unrelated mouse isotype control IgG2a. One
representative data set from nine independent experiments is shown. (F) Same as (D&E) but the results are expressed as the mean percentage of
apoptotic cells 6 SEM from nine separate experiments. (G) MDN (left panel) and XG2 (right panel) cells were incubated for one hour at 37uCi n
medium either with or without 10 mM TQ prior to a further incubation for one hour at 37uC with or without 10 mM Casp II. The cells were then starved
for 24 h in the presence of 1 mg/ml B-G27 mAb, and the percentage of apoptotic cells was determined by flow cytometry. The results are expressed
as the mean percentage of apoptotic cells 6 SEM from nine separate experiments.
doi:10.1371/journal.pone.0023741.g006
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(Fig. 6G).
Discussion
Although the pro-apoptotic and cytostatic (growth arrest) effects
of TQ on numerous cancer cells have been known for many years
[25,26,27,28,29,30,31], very little is known concerning its effects
on MM cells. Here, we investigated the effects of TQ on two
different MM cell lines (MDN and XG2) as well as on primary
plasma cells isolated from the BM of MM patients. Because
chemotaxis is important and critical for the homing, interaction
with the BM microenvironment and survival of MM cells, we first
assessed: (i) the chemokine receptor expression patterns of MDN
and XG2 cells; (ii) their migratory capacity toward various
chemokines and (iii) the signaling pathways activated upon their
stimulation with chemokines. We showed that MDN and XG2
cells strongly expressed CCR9, CXCR3 and CXCR4; expressed
low levels of CCR1, CCR5, CCR7 and CXCR5 and did not
express CCR6. Among these chemokine receptors, we showed
that only CXCR4 was fully functional and enabled MDN and
XG2 cells to specifically migrate in response to CXCL12. Our
results are in agreement with reports showing that CXCL12,
through activation of CXCR4, attracts human MM cells to the
endothelial border, as well as cells from MM cell lines such as
5T33MM cells [43,44].
The signaling pathways involved in CXCL-12-mediated MM
cell chemotaxis are poorly defined and require further clarifica-
tion. We therefore analyzed the effects of various inhibitors on the
CXCL12-mediated MDN and XG2 cell chemotaxis. Our results
provided strong evidence for the involvement of PLC, Class II
PI3K/AKT/Rho-A, IkBa/NFkB and ERK, but not of Class I
PI3K or P38 MAPK, in CXCL-12/CXCR4-mediated MM cell
chemotaxis. This is in agreement with a previously published
report that demonstrated (i) the involvement of PI3K and ERK
but not P38 in CXCL-12-mediated MM cell chemotaxis and (ii)
that AMD3100 significantly inhibits the homing of MM cells to
the BM [20]. To better define and confirm the signaling pathways
activated following the interaction of CXCL-12 with CXCR4 in
MDN and XG2 cells, we performed western blot analyses. We
found that CXCL12 specifically enhanced PLCb3 and ERK1/2
phosphorylation as well as Rho-A activation, but had no effect on
P38MAPK phosphorylation. Since previous studies of acute
lymphoblastic leukemia have demonstrated that p38 MAPK is a
critical regulator of cell migration [45], our findings highlight the
differences in the signaling pathways activated in various
malignant cell types.
Fernandis et al. showed that CXCL12 stimulation induces the
association of CXCR4 with CD45 in the Jurkat T-cell line [40].
Since Na3VO4 inhibited the CXCL12-mediated chemotaxis of
MDN and XG2 cells, we hypothesized that the membrane
tyrosine phosphatase CD45 may be involved in CXCL12-
mediated MM cell chemotaxis. Accordingly, we showed that
CXCL12-mediated MM cell chemotaxis requires the association
of CXCR4 with CD45. This is an important finding since CD45 is
a critical regulator of signaling thresholds in immune cells [46] that
regulates the retention, motility, and numbers of hematopoietic
progenitors in the BM [47]. More importantly, we found that the
CXCL12-induced association of CXCR4 with CD45 is strongly
inhibited by pre-treating MM cells with TQ, and our results
suggest that this inhibition is dependent on TQ-mediated down-
regulation of CXCR4 expression. Nevertheless, such CXCR4
down-regulation likely represents an important TQ mechanism of
action because we also showed that TQ decreases CXCL12-
mediated MM cell chemotaxis in a dose- and time-dependent
manner. Such TQ-mediated CXCR4 down-regulation could be
particularly relevant for clinicians, in light of the report by Alsayed
et al. showing that disease activity is inversely correlated with
CXCR4 expression levels on MM cells [20]. Finally, it is worth
noting that TQ inhibited CXCL12-mediated chemotaxis in MM
cells but not in PBMCs isolated from healthy individuals.
Furthermore, TQ did not affect cell viability, highlighting the fact
that TQ exerts a potent and specific effect on MM cells without
inducing any cytotoxic effect.
Another major finding emerging from the present study is the
demonstration that the surface expression of CD95 is strongly
increased on TQ-treated MM cells. We showed that this up-
regulation results from the relocation of intracellular CD95 to the
cell membrane and not from de novo protein synthesis. Such
relocation of intracellular CD95 to the cell surface has previously
been observed in other cell types, e.g. in untransformed human
vascular smooth muscle cells and pancreatic b-cells following p53
activation and/or their stimulation with interferon gamma
[48,49,50]. In particular, Bennett et al. specifically showed that
the intracellular CD95 was localized to the Golgi complex and
trans-Golgi network, and its relocation to the cell membrane did
not require protein synthesis [48]. It is however worth mentioning
that the requirement of protein and RNA synthesis for the
translocation of CD95 to the cell surface appears to be dependent
on the cell type under investigation [50]. CD95 plays a major role
in apoptosis. Indeed, stimulating CD95 via an agonistic anti-CD95
antibody or its ligand (CD95L) results in CD95 oligomerization
and formation of the death-inducing signaling complex (DISC),
which in turn activates a series of caspases and results in apoptotic
cell death [51]. Therefore, we investigated whether TQ-mediated
CD95 up-regulation was functionally significant and increased
MM cell susceptibility to apoptosis. Our results showed that TQ
treatment increases CD95-mediated, caspase-dependent apoptosis
of MM cells by up to 85%. To our knowledge, we show here for
the first time that TQ up-regulates CD95 expression on the
surface of MM cells and increases their susceptibility to Fas-
mediated apoptosis. Interestingly, Gali-Muhtasib et al. previously
reported a pro-apoptotic activity of TQ treatment, though in a
different cancer model (colorectal cancer cells) and involving a
different mechanism of action (triggering the inactivation of the
stress response pathway sensor CHEK1) [52]. Recently, Li et al.
also reported that TQ inhibits the proliferation and induces the
apoptosis of MM cells through the suppression of stat3 activation
pathway [53]. In conclusion, the present data expand our
knowledge of TQ mechanism of action and suggest that TQ
may represent a promising drug candidate for the treatment of
patients with MM, providing a rationale for its clinical evaluation.
Supporting Information
Figure S1 Chemokine receptor expression by MM cells.
The chemokine receptor expression levels (gray filled histograms)
of XG2 cells were determined by flow cytometry using specific
monoclonal antibodies (mAbs). Cells stained with an isotype-
matched mAb are shown as a negative control (thin solid line
histograms). One representative data set from four independent
experiments is shown.
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